FDA May Delay Part 11 Revision To 'Get It Right,' Official Says

Drug GMP Report
KEYWORDS FDA / Part 11
A A

The FDA is unlikely to complete its long-awaited revision of 21 CFR Part 11 by the end of the year as planned, an agency official said this month.

To View This Article:

Login

Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $10.00